Open an account

Fractyl Health

GUTS · NASDAQ

$1.33−$0.05 (−3.62%)TodayMarket closed ·
Prev close $1.38

About GUTS

Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.

Employees
100
Headquarters
Burlington, Massachusetts
Listed
Feb 2, 2024
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
fractyl.com

GUTS key statistics

Market cap
17.64M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
949.80K
Volume
477.98K
Open price
$1.39
High today
$1.48
Low today
$1.33
52 Week high
$29.34
52 Week low
$1.37

Fractyl Health (GUTS) at a glance

Fractyl Health (GUTS) last traded at $1.33, with a market cap of 17.64M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.33 and $1.48. The current price is 0.0% above the day's low and 10.1% below its high.

Volume so far is 477.98K shares, below the average of 949.80K shares a day.

Over the past year Fractyl Health has ranged from $1.37 to $29.34, and now sits 0% of the way up that range.

Fractyl Health met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.92 per share against an estimate of -$1.65.

The average analyst price target is $4.53, 240.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.53
Low
$2.02
Now
$1.33
High
$8.40

GUTS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 29.4% on average.

  1. Q3 FY24: reported -$0.48 per share against an estimate of -$0.51
  2. Q4 FY24: reported -$0.52 per share against an estimate of -$0.4437
  3. Q1 FY25: reported -$0.49 per share against an estimate of -$0.4862
  4. Q2 FY25: reported -$0.57 per share against an estimate of -$0.3672
  5. Q3 FY25: reported -$0.71 per share against an estimate of -$0.3223
  6. Q4 FY25: reported -$0.07 per share against an estimate of -$0.1836
  7. Q1 FY26: reported -$1.56 per share against an estimate of -$1.96
  8. Q2 FY26: reported -$1.92 per share against an estimate of -$1.65

GUTS news

  • Press releaseBusiness Wire

    GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

  • Press releasePRNewswire

    INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm

  • Press releaseGlobe Newswire

    GUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

  • Avi Kapoor

    Crude Oil Jumps 3%; Citizens Financial Earnings Top Views

  • Vandana Singh

    Why Fractyl Health Stock Is Sinking Friday

  • Avi Kapoor

    Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings

  • Press releasePRNewswire

    SueWallSt Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS

  • Press releaseGlobe Newswire

    GUTS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

Similar companies

Companies in the same industry as Fractyl Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.